Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.

Corey C FordJeffrey A CohenAndrew D GoodmanJ William LindseyRobert P LisakChristopher LuzzioAmy PruittJohn RoseHorea RusJerry S WolinskyShaul E KadoshEmily Bernstein-HanlonYafit StarkJessica K Alexander

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)

GA long-term treatment maintained clinical benefit with a similar safety profile to phase 3 results; a key limitation was that only 25% of participants completed the OLE. Early initiation of GA had sustained benefits versus delayed treatment.

Keyphrases

open label
pet ct
clinical trial
radiation therapy
phase iii